Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 16.231
Filtrar
Más filtros











Intervalo de año de publicación
1.
Bull Math Biol ; 86(7): 83, 2024 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-38842602

RESUMEN

5-Aminolevulinic Acid (5-ALA) is the only fluorophore approved by the FDA as an intraoperative optical imaging agent for fluorescence-guided surgery in patients with glioblastoma. The dosing regimen is based on rodent tests where a maximum signal occurs around 6 h after drug administration. Here, we construct a computational framework to simulate the transport of 5-ALA through the stomach, blood, and brain, and the subsequent conversion to the fluorescent agent protoporphyrin IX at the tumor site. The framework combines compartmental models with spatially-resolved partial differential equations, enabling one to address questions regarding quantity and timing of 5-ALA administration before surgery. Numerical tests in two spatial dimensions indicate that, for tumors exceeding the detection threshold, the time to peak fluorescent concentration is 2-7 h, broadly consistent with the current surgical guidelines. Moreover, the framework enables one to examine the specific effects of tumor size and location on the required dose and timing of 5-ALA administration before glioblastoma surgery.


Asunto(s)
Ácido Aminolevulínico , Neoplasias Encefálicas , Simulación por Computador , Glioblastoma , Conceptos Matemáticos , Modelos Biológicos , Protoporfirinas , Cirugía Asistida por Computador , Glioblastoma/cirugía , Glioblastoma/tratamiento farmacológico , Glioblastoma/patología , Glioblastoma/diagnóstico por imagen , Ácido Aminolevulínico/administración & dosificación , Humanos , Neoplasias Encefálicas/cirugía , Protoporfirinas/administración & dosificación , Protoporfirinas/metabolismo , Cirugía Asistida por Computador/métodos , Animales , Fármacos Fotosensibilizantes/administración & dosificación , Imagen Óptica/métodos , Colorantes Fluorescentes/administración & dosificación
2.
Planta Med ; 90(7-08): 588-594, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38843798

RESUMEN

Antimicrobial photodynamic therapy (aPDT) is an evolving treatment strategy against human pathogenic microbes such as the Candida species, including the emerging pathogen C. auris. Using a modified EUCAST protocol, the light-enhanced antifungal activity of the natural compound parietin was explored. The photoactivity was evaluated against three separate strains of five yeasts, and its molecular mode of action was analysed via several techniques, i.e., cellular uptake, reactive electrophilic species (RES), and singlet oxygen yield. Under experimental conditions (λ = 428 nm, H = 30 J/cm2, PI = 30 min), microbial growth was inhibited by more than 90% at parietin concentrations as low as c = 0.156 mg/L (0.55 µM) for C. tropicalis and Cryptococcus neoformans, c = 0.313 mg/L (1.10 µM) for C. auris, c = 0.625 mg/L (2.20 µM) for C. glabrata, and c = 1.250 mg/L (4.40 µM) for C. albicans. Mode-of-action analysis demonstrated fungicidal activity. Parietin targets the cell membrane and induces cell death via ROS-mediated lipid peroxidation after light irradiation. In summary, parietin exhibits light-enhanced fungicidal activity against all Candida species tested (including C. auris) and Cryptococcus neoformans, covering three of the four critical threats on the WHO's most recent fungal priority list.


Asunto(s)
Antifúngicos , Cryptococcus neoformans , Pruebas de Sensibilidad Microbiana , Antifúngicos/farmacología , Cryptococcus neoformans/efectos de los fármacos , Cryptococcus neoformans/efectos de la radiación , Candida auris/efectos de los fármacos , Luz , Candida/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismo , Fotoquimioterapia/métodos , Antraquinonas/farmacología , Fármacos Fotosensibilizantes/farmacología
3.
J Refract Surg ; 40(6): e392-e397, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38848056

RESUMEN

PURPOSE: To compare the effects of corneal allogenic intrastromal ring segment (CAIRS) implantation on topographical measurements and visual outcomes of patients with keratoconus with and without corneal cross-linking (CXL) prior to the time of implantation. METHODS: Sixty-seven eyes with corneal allograft intrastromal ring segment implantation (KeraNatural; Lions VisionGift) due to advanced keratoconus were included in the study. Thirty-seven eyes had no CXL and 30 eyes had had CXL before being referred to the authors. The changes in spherical equivalent (SE), uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), steep keratometry (K1), flat keratometry (K2), mean keratometry (Kmean), maximum keratometry (Kmax), and thinnest pachymetry were retrospectively analyzed 6 months after the implantation. RESULTS: The median age was 29 years in the CXL group and 24.0 years in the non-CXL group (P > .05), respectively. All topographical and visual parameters before implantation were similar in both groups (P > .05 for all parameters). At 6 months, CDVA, K1, and Kmean showed higher improvement in the non-CXL group than the CXL group (P = .030, .018, and .039, respectively). CONCLUSIONS: CAIRS surgery has a flattening effect on both the corneas with and without CXL. The cornea with prior CXL treatment had less flattening effect due to the stiffening effect of prior CXL. [J Refract Surg. 2024;40(6):e392-e397.].


Asunto(s)
Colágeno , Sustancia Propia , Topografía de la Córnea , Reactivos de Enlaces Cruzados , Queratocono , Fármacos Fotosensibilizantes , Prótesis e Implantes , Implantación de Prótesis , Refracción Ocular , Agudeza Visual , Humanos , Queratocono/fisiopatología , Queratocono/metabolismo , Queratocono/tratamiento farmacológico , Queratocono/cirugía , Sustancia Propia/metabolismo , Sustancia Propia/cirugía , Reactivos de Enlaces Cruzados/uso terapéutico , Agudeza Visual/fisiología , Adulto , Masculino , Femenino , Fármacos Fotosensibilizantes/uso terapéutico , Estudios Retrospectivos , Adulto Joven , Refracción Ocular/fisiología , Colágeno/metabolismo , Paquimetría Corneal , Riboflavina/uso terapéutico , Fotoquimioterapia/métodos , Adolescente , Rayos Ultravioleta , Trasplante de Córnea/métodos , Persona de Mediana Edad , Reticulación Corneal
4.
Biomed Mater ; 19(4)2024 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-38697132

RESUMEN

During the process of malignant tumor treatment, photodynamic therapy (PDT) exerts poor efficacy due to the hypoxic environment of the tumor cells, and long-time chemotherapy reduces the sensitivity of tumor cells to chemotherapy drugs due to the presence of drug-resistant proteins on the cell membranes for drug outward transportation. Therefore, we reported a nano platform based on mesoporous silica coated with polydopamine (MSN@PDA) loading PDT enhancer MnO2, photosensitizer indocyanine green (ICG) and chemotherapeutic drug doxorubicin (DOX) (designated as DMPIM) to achieve a sequential release of different drugs to enhance treatment of malignant tumors. MSN was first synthesized by a template method, then DOX was loaded into the mesoporous channels of MSN, and locked by the PDA coating. Next, ICG was modified by π-π stacking on PDA, and finally, MnO2layer was accumulated on the surface of DOX@MSN@PDA- ICG@MnO2, achieving orthogonal loading and sequential release of different drugs. DMPIM first generated oxygen (O2) through the reaction between MnO2and H2O2after entering tumor cells, alleviating the hypoxic environment of tumors and enhancing the PDT effect of sequentially released ICG. Afterwards, ICG reacted with O2in tumor tissue to produce reactive oxygen species, promoting lysosomal escape of drugs and inactivation of p-glycoprotein (p-gp) on tumor cell membranes. DOX loaded in the MSN channels exhibited a delay of approximately 8 h after ICG release to exert the enhanced chemotherapy effect. The drug delivery system achieved effective sequential release and multimodal combination therapy, which achieved ideal therapeutic effects on malignant tumors. This work offers a route to a sequential drug release for advancing the treatment of malignant tumors.


Asunto(s)
Doxorrubicina , Liberación de Fármacos , Verde de Indocianina , Indoles , Compuestos de Manganeso , Óxidos , Fotoquimioterapia , Fármacos Fotosensibilizantes , Polímeros , Fotoquimioterapia/métodos , Doxorrubicina/química , Doxorrubicina/farmacología , Doxorrubicina/administración & dosificación , Verde de Indocianina/química , Indoles/química , Animales , Compuestos de Manganeso/química , Humanos , Polímeros/química , Línea Celular Tumoral , Óxidos/química , Fármacos Fotosensibilizantes/química , Dióxido de Silicio/química , Ratones , Antineoplásicos/química , Antineoplásicos/farmacología , Antineoplásicos/administración & dosificación , Neoplasias/tratamiento farmacológico , Especies Reactivas de Oxígeno/metabolismo , Sistemas de Liberación de Medicamentos , Nanopartículas/química , Portadores de Fármacos/química , Porosidad
5.
Artif Cells Nanomed Biotechnol ; 52(1): 270-277, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38696132

RESUMEN

Spherical gold/polyacrylic acid (Au/PAA) polymer-inorganic Janus nanoparticles (JNPs) with simultaneous therapeutic and targeting functions were fabricated. The obtained Au/PAA JNPs were further selectively functionalized with folic acid (FA) and thiol PEG amine (SH-PEG-NH2) on Au sides to provide superior biocompatibility and active targeting, while the other PAA sides were loaded with 5-aminolevulinic acid (5-ALA) to serve as a photosensitizer (PS) for photodynamic therapeutic (PDT) effects on MCF-7 cancer cells. The PS loading of 5-ALA was found to be 83% with an average hydrodynamic size and z-potential of 146 ± 0.8 nm and -6.40 mV respectively for FA-Au/PAA-ALA JNPs. The in vitro PDT study of the JNPs on MCF-7 breast cancer cells under 636 nm laser irradiation indicated the cell viability of 24.7% ± 0.5 for FA-Au/PAA-ALA JNPs at the IC50 value of 0.125 mM. In this regard, the actively targeted FA-Au/PAA-ALA JNPs treatment holds great potential for tumour therapy with high cancer cell-killing efficacy.


Asunto(s)
Ácido Aminolevulínico , Neoplasias de la Mama , Oro , Fotoquimioterapia , Fármacos Fotosensibilizantes , Humanos , Células MCF-7 , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Neoplasias de la Mama/metabolismo , Ácido Aminolevulínico/química , Ácido Aminolevulínico/farmacología , Oro/química , Oro/farmacología , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/farmacología , Nanopartículas/química , Resinas Acrílicas/química , Femenino , Ácido Fólico/química , Supervivencia Celular/efectos de los fármacos
6.
BMC Ophthalmol ; 24(1): 201, 2024 May 03.
Artículo en Inglés | MEDLINE | ID: mdl-38698363

RESUMEN

BACKGROUND: We aimed to employ Optical Coherence Tomography Angiography (OCTA) to comprehensively assess changes in the optic nerve head (ONH) and macular perfusion before and after the Corneal Collagen Cross-Linking (CCL) procedure in patients with keratoconus. METHODS: A total of 22 keratoconus patient's candidate for CCL procedures were included based on specific criteria, with meticulous exclusion criteria in place to minimize potential confounders. Participants underwent OCTA assessments of the ONH and macula using the Spectralis OCT (Heidelberg) before CCL, as well as at 1- and 3-months post-CCL. MATLAB software was utilized for image analysis. RESULTS: The mean age of the participants was 20.09 ± 6.11, including 59% male, and the mean intraocular pressure (IOP) before the surgery was 13.59 ± 2.85 mmHg. Peripapillary Retinal nerve fiber layer (ppRNFL) thickness and overall retinal thickness remained stable post-CCL. However, significant alterations were observed in macular vessel density, emphasizing regional variations in vascular response. For macular large vessel density (LVD), both superficial and deep vascular complex (SVC and DVC) demonstrated significant differences between before surgery and the 3 months post-surgery follow-up (p < 0.001 and p = 0.002, respectively). Optic nerve head markers demonstrated relative stability, except for changes in avascular complex density, which was 49.2 ± 2.2% before the surgery and decrease to 47.6 ± 1.7% three months after the operation (P-value = 0.005). CONCLUSION: While CCL appears to maintain the integrity of certain ocular structures, alterations in macular perfusion post-CCL suggest potential effects on retinal blood supply. Long-term monitoring is crucial to understand the implications of these changes, particularly in the context of conditions such as diabetes.


Asunto(s)
Colágeno , Reactivos de Enlaces Cruzados , Angiografía con Fluoresceína , Queratocono , Disco Óptico , Vasos Retinianos , Tomografía de Coherencia Óptica , Humanos , Tomografía de Coherencia Óptica/métodos , Queratocono/fisiopatología , Queratocono/diagnóstico , Masculino , Femenino , Colágeno/metabolismo , Adulto Joven , Adulto , Angiografía con Fluoresceína/métodos , Vasos Retinianos/diagnóstico por imagen , Vasos Retinianos/fisiopatología , Disco Óptico/irrigación sanguínea , Adolescente , Estudios Prospectivos , Fármacos Fotosensibilizantes/uso terapéutico , Fotoquimioterapia/métodos , Mácula Lútea/diagnóstico por imagen , Mácula Lútea/irrigación sanguínea
7.
Int J Nanomedicine ; 19: 4679-4699, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38803997

RESUMEN

Background: Breast cancer is a heterogeneous disease globally accounting for approximately 1 million new cases annually. Chemotherapy remains the main therapeutic option, but the antitumor efficacy needs to be improved. Methods: Two multifunctional nanoparticles were developed in this paper using oleic acid and mPEG2k-PCL2k as the drug carriers. Squamocin (Squ) was employed as a chemotherapeutic agent. Resiquimod (R848) or ginsenoside Rh2 was co-encapsulated in the nanoparticles to remold the immunosuppressive tumor microenvironment, and IR780 was coloaded as a photosensitizer to realize photothermal therapy. Results: The obtained Squ-R848-IR780 nanoparticles and Squ-Rh2-IR780 nanoparticles were uniformly spherical and approximately (162.200 ± 2.800) nm and (157.300 ± 1.1590) nm, respectively, in average diameter, with good encapsulation efficiency (above 85% for each drug), excellent stability in various physiological media and high photothermal conversion efficiency (24.10% and 22.58%, respectively). After intravenous administration, both nanoparticles quickly accumulated in the tumor and effectively enhanced the local temperature of the tumor to over 45 °C when irradiated by an 808 nm laser. At a low dose of 0.1 mg/kg, Squ nanoparticles treatment alone displayed a tumor inhibition rate of 55.28%, pulmonary metastasis inhibition rate of 59.47% and a mean survival time of 38 days, which were all higher than those of PTX injection (8 mg/kg) (43.64%, 25 days and 37.25%), indicating that Squ was a potent and effective antitumor agent. Both multifunctional nanoparticles, Squ-Rh2-IR780 nanoparticles and Squ-R848-IR780 nanoparticles, demonstrated even better therapeutic efficacy, with tumor inhibition rates of 90.02% and 97.28%, pulmonary metastasis inhibition rates of 95.42% and 98.09, and mean survival times of 46 days and 52 days, respectively. Conclusion: The multifunctional nanoparticles coloaded with squamocin, R848 and IR 780 achieved extraordinary therapeutic efficacy and excellent antimetastasis activity and are thus promising in the future treatment of breast tumors and probably other tumors.


Asunto(s)
Neoplasias de la Mama , Indoles , Nanopartículas , Femenino , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Animales , Nanopartículas/química , Humanos , Indoles/química , Indoles/farmacología , Línea Celular Tumoral , Ratones , Portadores de Fármacos/química , Antineoplásicos/química , Antineoplásicos/farmacología , Terapia Fototérmica/métodos , Ratones Endogámicos BALB C , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/administración & dosificación , Imidazoles/química , Imidazoles/farmacología , Imidazoles/administración & dosificación , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/patología , Microambiente Tumoral/efectos de los fármacos
8.
Int J Nanomedicine ; 19: 4163-4180, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38751660

RESUMEN

Purpose: The study aimed to address the non-specific toxicity of cytotoxins (CTX) in liver cancer treatment and explore their combined application with the photosensitizer Ce6, co-loaded into carbonized Zn/Co bimetallic organic frameworks. The goal was to achieve controlled CTX release and synergistic photodynamic therapy, with a focus on evaluating anti-tumor activity against human liver cancer cell lines (Hep G2). Methods: Purified cobra cytotoxin (CTX) and photosensitizer Ce6 were co-loaded into carbonized Zn/Co bimetallic organic frameworks, resulting in RGD-PDA@C-ZIF@(CTX+Ce6). The formulation was designed with surface-functionalization using polydopamine and tumor-penetrating peptide RGD. This approach aimed to facilitate controlled CTX release and enhance the synergistic effect of photodynamic therapy. The accumulation of RGD-PDA@C-ZIF@(CTX+Ce6) at tumor sites was achieved through RGD's active targeting and the enhanced permeability and retention (EPR) effect. In the acidic tumor microenvironment, the porous structure of the metal-organic framework disintegrated, releasing CTX and Ce6 into tumor cells. Results: Experiments demonstrated that RGD-PDA@C-ZIF@(CTX+Ce6) nanoparticles, combined with near-infrared laser irradiation, exhibited optimal anti-tumor effects against human liver cancer cells. The formulation showcased heightened anti-tumor activity without discernible systemic toxicity. Conclusion: The study underscores the potential of utilizing metal-organic frameworks as an efficient nanoplatform for co-loading cytotoxins and photodynamic therapy in liver cancer treatment. The developed formulation, RGD-PDA@C-ZIF@(CTX+Ce6), offers a promising avenue for advancing the clinical application of cytotoxins in oncology, providing a solid theoretical foundation for future research and development.


Asunto(s)
Indoles , Neoplasias Hepáticas , Estructuras Metalorgánicas , Fotoquimioterapia , Fármacos Fotosensibilizantes , Zinc , Humanos , Fotoquimioterapia/métodos , Estructuras Metalorgánicas/química , Estructuras Metalorgánicas/farmacología , Neoplasias Hepáticas/tratamiento farmacológico , Zinc/química , Zinc/farmacología , Indoles/química , Indoles/farmacología , Indoles/administración & dosificación , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/administración & dosificación , Animales , Células Hep G2 , Cobalto/química , Cobalto/farmacología , Oligopéptidos/química , Oligopéptidos/farmacología , Oligopéptidos/farmacocinética , Polímeros/química , Ratones , Citotoxinas/química , Citotoxinas/farmacología , Citotoxinas/farmacocinética , Ratones Desnudos , Ratones Endogámicos BALB C , Supervivencia Celular/efectos de los fármacos
9.
Proc Natl Acad Sci U S A ; 121(20): e2321545121, 2024 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-38713621

RESUMEN

The efficiency of photodynamic therapy (PDT) is greatly dependent on intrinsic features of photosensitizers (PSs), but most PSs suffer from narrow diffusion distances and short life span of singlet oxygen (1O2). Here, to conquer this issue, we propose a strategy for in situ formation of complexes between PSs and proteins to deactivate proteins, leading to highly effective PDT. The tetrafluorophenyl bacteriochlorin (FBC), a strong near-infrared absorbing photosensitizer, can tightly bind to intracellular proteins to form stable complexes, which breaks through the space-time constraints of PSs and proteins. The generated singlet oxygen directly causes the protein dysfunction, leading to high efficiency of PSs. To enable efficient delivery of PSs, a charge-conversional and redox-responsive block copolymer POEGMA-b-(PAEMA/DMMA-co-BMA) (PB) was designed to construct a protein-binding photodynamic nanoinhibitor (FBC@PB), which not only prolongs blood circulation and enhances cellular uptake but also releases FBC on demand in tumor microenvironment (TME). Meanwhile, PDT-induced destruction of cancer cells could produce tumor-associated antigens which were capable to trigger robust antitumor immune responses, facilitating the eradication of residual cancer cells. A series of experiments in vitro and in vivo demonstrated that this multifunctional nanoinhibitor provides a promising strategy to extend photodynamic immunotherapy.


Asunto(s)
Fotoquimioterapia , Fármacos Fotosensibilizantes , Microambiente Tumoral , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/uso terapéutico , Animales , Humanos , Ratones , Microambiente Tumoral/efectos de los fármacos , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismo , Línea Celular Tumoral , Oxígeno Singlete/metabolismo , Porfirinas/farmacología , Porfirinas/química , Unión Proteica , Nanopartículas/química
10.
Lasers Med Sci ; 39(1): 131, 2024 May 16.
Artículo en Inglés | MEDLINE | ID: mdl-38750381

RESUMEN

Photodynamic therapy (PDT) is a targeted treatment method that utilizes a photosensitizer (PS) to induce cytotoxicity in malignant and non-malignant tumors. Optimization of PDT requires investigation of the selectivity of PS for the target tissues, irradiating light source, irradiation wavelengths, fluence rate, fluence, illumination mode, and overall treatment plan. In this study, we developed the Multi-mode Automatized Well-plate PDT LED Laboratory Irradiation System (MAWPLIS), an innovative device that automates time-consuming well plate light dosage/PS dose measurement experiment. The careful control of LED current and temperature stabilization in the LED module allowed the system to achieve high optical output stability. The MAWPLIS was designed by integrating a 3-axis moving system and motion controller, a quick-switching LED controller unit equipped with interchangeable LED modules capable of employing multiple wavelengths, and a TEC system. The proposed system achieved high optical output stability (1 mW) within the range of 0-500 mW, high wavelength stability (5 nm) at 635 nm, and high temperature stability (0.2 °C) across all radiation modes. The system's validation involved in vitro analysis using 5-ALA across varying concentrations, incubation periods, light exposures, and wavelengths in HT-29 colon cancer and WI-38 human lung fibroblast cell lines. Specifically, a combination of 405 nm and 635 nm wavelengths was selected to demonstrate enhanced strategies for colon cancer cell eradication and system validation. The MAWPLIS system represents a significant advancement in photodynamic therapy (PDT) research, offering automation and standardization of time-intensive experiments, high stability and precision, and improved PDT efficacy through dual-wavelength integration.


Asunto(s)
Fotoquimioterapia , Fármacos Fotosensibilizantes , Fotoquimioterapia/métodos , Fotoquimioterapia/instrumentación , Humanos , Células HT29 , Ácido Aminolevulínico/administración & dosificación
12.
Artif Cells Nanomed Biotechnol ; 52(1): 309-320, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38781462

RESUMEN

Photodynamic therapy (PDT) holds great potential to overcome limitations associated with common colorectal cancer (CRC) treatment approaches. Targeted photosensitiser (PS) delivery systems using nanoparticles (NPs) with targeting moieties are continually being designed, which are aimed at enhancing PS efficacy in CRC PDT. However, the optimisation of targeted PS delivery systems in most, in vitro PDT studies has been conducted on two dimensional (2D) monolayers cell cultures. In our present study, we developed a nano PS delivery system for in vitro cultured human colorectal three-dimensional multicellular spheroids (3D MCTS). PEGylated gold nanoparticles (PEG-AuNPs) were prepared and attached to ZnPcS4PS and further functionalised with specific CRC targeting anti-Guanylate Cyclase monoclonal antibodies(mAb). The ZnPcS4-AuNP-Anti-GCC Ab (BNC) nanoconjugates were successfully synthesised and their photodynamic effect investigated following exposure to laser irradiation and demonstrated enhanced anticancer effects in Caco-2 cells cultivated as 3D MCTS spheroids. Our findings suggest that targeted BNC nanoconjugates can improve the efficacy of PDT and highlight the potential of 3D MCTS tumour model for evaluating of targeted PDT.


Asunto(s)
Neoplasias Colorrectales , Oro , Nanopartículas del Metal , Fotoquimioterapia , Esferoides Celulares , Humanos , Oro/química , Oro/farmacología , Esferoides Celulares/efectos de los fármacos , Esferoides Celulares/patología , Esferoides Celulares/metabolismo , Neoplasias Colorrectales/patología , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/metabolismo , Nanopartículas del Metal/química , Células CACO-2 , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/química , Polietilenglicoles/química
13.
Photodiagnosis Photodyn Ther ; 45: 103869, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38787766

RESUMEN

BACKGROUND: For malignant glioma, intraoperative photodynamic therapy (PDT) using talaporfin sodium is a powerful tool for local tumor control, when gross total removal is performed. However, the efficacy of PDT for non-totally resectable malignant glioma has not been clearly confirmed. Therefore, the purpose of this study was to clarify the usefulness of PDT using talaporfin sodium for non-totally resectable malignant glioma. METHODS: Eighteen patients with malignant glioma (16 new onset, 2 recurrent) in whom gross total removal was judged to be difficult from the images obtained before surgery were evaluated. Fifteen patients had glioblastoma (14 newly diagnosed, 1 recurrent), and 3 patients had anaplastic oligodendroglioma (2 newly diagnosed, 1 recurrent). The whole resection cavity was subjected to PDT during the surgery. For newly diagnosed glioblastoma, postoperative therapy involved the combined use of radiation and temozolomide. Bevacizumab treatment was also started at an early stage after surgery. RESULTS: In some patients, reduction of the residual tumor was observed at an early stage of chemoradiotherapy after the surgery, suggesting the positive effect of PDT. Recurrence occurred in 15 of the 18 patients during the course of treatment. Distant recurrence occurred in 8 of these 15 patients, despite good local tumor control. In the 14 patients with newly diagnosed glioblastoma, the median progression-free survival was almost 10.5 months, and the median overall survival was almost 16.9 months. CONCLUSIONS: PDT for malignant glioma is expected to slightly improve local tumor control for non-totally resectable lesions.


Asunto(s)
Neoplasias Encefálicas , Glioma , Fotoquimioterapia , Fármacos Fotosensibilizantes , Porfirinas , Humanos , Fotoquimioterapia/métodos , Masculino , Femenino , Fármacos Fotosensibilizantes/uso terapéutico , Porfirinas/uso terapéutico , Persona de Mediana Edad , Glioma/tratamiento farmacológico , Anciano , Adulto , Neoplasias Encefálicas/tratamiento farmacológico , Recurrencia Local de Neoplasia , Temozolomida/uso terapéutico
14.
J Biol Inorg Chem ; 29(3): 303-314, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38727821

RESUMEN

This study demonstrates the potential of sono-photodynamic therapy as an effective approach for enhancing singlet oxygen generation using the synthesized Schiff-base diaxially substituted silicon phthalocyanines. In photochemical studies, the singlet oxygen quantum yields (Φ∆) were determined as 0.43 for Si1a, 0.94 for Q-Si1a, 0.58 for S-Si1a, and 0.49 for B-Sia1. In sono-photochemical studies, the Φ∆ values were reached to 0.67 for Si1a, 1.06 for Q-Si1a, 0.65 for S-Si1a, and 0.67 for B-Sia1. In addition, this study demonstrates the therapeutic efficacy of phthalocyanines synthesized as sensitizers on the PC3 prostate cancer cell line through in vitro experiments. The application of these treatment modalities exhibited notable outcomes, leading to a substantial decrease in cell viability within the PC3 prostate cancer cell line. These findings highlight the potential of utilizing these synthesized phthalocyanines as promising therapeutic agents for prostate cancer treatment.


Asunto(s)
Supervivencia Celular , Indoles , Compuestos de Organosilicio , Neoplasias de la Próstata , Bases de Schiff , Oxígeno Singlete , Humanos , Indoles/química , Indoles/farmacología , Bases de Schiff/química , Bases de Schiff/farmacología , Masculino , Oxígeno Singlete/metabolismo , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/metabolismo , Compuestos de Organosilicio/química , Compuestos de Organosilicio/farmacología , Supervivencia Celular/efectos de los fármacos , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/síntesis química , Antineoplásicos/farmacología , Antineoplásicos/química , Antineoplásicos/síntesis química , Ensayos de Selección de Medicamentos Antitumorales , Células PC-3 , Fotoquimioterapia , Procesos Fotoquímicos , Línea Celular Tumoral , Estructura Molecular
15.
Luminescence ; 39(5): e4770, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38751216

RESUMEN

The ultimate goal of nanoparticle-based phototherapy is to suppress tumor growth. Photothermal therapy (PTT) and photothermal photodynamic therapy (PDT) are two types of physicochemical therapy that use light radiation with multiple wavelength ranges in the near-infrared to treat cancer. When a laser is pointed at tissue, photons are taken in the intercellular and intracellular regions, converting photon energy to heat. It has attracted much interest and research in recent years. The advent of transition materials dichalcogenides (TMDCs) is a revolutionary step in PDT/PTT-based cancer therapy. The TMDCs is a multilayer 2D nano-composite. TMDCs contain three atomic layers in which two chalcogens squash in the transition metal. The chalcogen atoms are highly reactive, and the surface characteristics of TMDCs help them to target deep cancer cells. They absorb Near Infrared (NIR), which kills deep cancer cells. In this review, we have discussed the history and mechanism of PDT/PTT and the use of TMDCs and nanoparticle-based systems, which have been practiced for theranostics purposes. We have also discussed PDT/PTT combined with immunotherapy, in which the cancer cell apoptosis is done by activating the immune cells, such as CD8+.


Asunto(s)
Neoplasias , Fotoquimioterapia , Terapia Fototérmica , Elementos de Transición , Humanos , Neoplasias/tratamiento farmacológico , Neoplasias/terapia , Neoplasias/patología , Elementos de Transición/química , Elementos de Transición/farmacología , Calcógenos/química , Calcógenos/farmacología , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/farmacología , Animales
16.
Lasers Med Sci ; 39(1): 135, 2024 May 24.
Artículo en Inglés | MEDLINE | ID: mdl-38787412

RESUMEN

In this study, we assess the impact of photodynamic therapy (PDT) using aluminum phthalocyanine tetrasulfonate (AlPcS4) on the viability and cellular stress responses of MCF-7 breast cancer cells. Specifically, we investigate changes in cell viability, cytokine production, and the expression of stress-related genes. Experimental groups included control cells, those treated with AlPcS4 only, light-emitting diode (LED) only, and combined PDT. To evaluate these effects on cell viability, cytokine production, and the expression of stress-related genes, techniques such as 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, enzyme-linked immunosorbent assays (ELISA), and real-time quantitative PCR (RT‒qPCR) were employed. Our findings reveal how PDT with AlPcS4 modulates mitochondrial activity and cytokine responses, shedding light on the cellular pathways essential for cell survival and stress adaptation. This work enhances our understanding of PDT's therapeutic potential and mechanisms in treating breast cancer.


Asunto(s)
Neoplasias de la Mama , Supervivencia Celular , Citocinas , Indoles , Compuestos Organometálicos , Fotoquimioterapia , Fármacos Fotosensibilizantes , Humanos , Fotoquimioterapia/métodos , Células MCF-7 , Citocinas/metabolismo , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/efectos de la radiación , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , Femenino , Compuestos Organometálicos/farmacología , Fármacos Fotosensibilizantes/farmacología , Indoles/farmacología , Proteínas de Choque Térmico/metabolismo , Proteínas de Choque Térmico/genética , Ensayo de Inmunoadsorción Enzimática
17.
Acta Derm Venereol ; 104: adv18308, 2024 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-38751175

RESUMEN

Photodynamic therapy is an approved treatment for primary, superficial, and small nodular basal cell carcinomas with a thickness of < 2 mm located on low-risk sites. Histologically verified basal cell carcinomas clinically assessed as suited for photodynamic therapy were included. The study aimed to investigate the agreement between clinical and histological assessments of basal cell carcinoma subtypes and thickness of tumours selected for photodynamic therapy with histopathological evaluation as a reference. A total of 343 tumours were included. The agreement between clinical and histological diagnosis of basal cell carcinoma subtype was 72% (p < 0.001). Clinical assessment of subtype had a sensitivity of 93% and specificity of 55% for superficial tumours and a sensitivity of 55% and specificity of 85% for nodular tumours. The mean ± SD thickness values by clinical and histological assessments were 0.95 ± 0.53 and 0.86 ± 0.75. The difference of 0.09 mm was statistically significant (p = 0.017), but not considered to be clinically relevant, although the differences between specific subgroups could be relevant. Among basal cell carcinomas clinically diagnosed as superficial, 91% were histologically consistent with the current photodynamic therapy criteria. The main results suggest that histopathological evaluation should precede photodynamic therapy to ensure selection of suitable basal cell carcinomas. In selected cases, the clinical diagnosis alone may be adequate before proceeding with photodynamic therapy.


Asunto(s)
Carcinoma Basocelular , Fotoquimioterapia , Neoplasias Cutáneas , Humanos , Carcinoma Basocelular/patología , Carcinoma Basocelular/tratamiento farmacológico , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/tratamiento farmacológico , Masculino , Femenino , Anciano , Persona de Mediana Edad , Anciano de 80 o más Años , Valor Predictivo de las Pruebas , Biopsia , Adulto , Selección de Paciente , Fármacos Fotosensibilizantes/uso terapéutico , Estudios Retrospectivos
18.
Curr Microbiol ; 81(7): 183, 2024 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-38771359

RESUMEN

The fungus Monascus is a well-known source of secondary metabolites with interesting pharmaceutical and nutraceutical applications. In particular, Monascus pigments possess a wide range of biological activities (e.g. antimicrobial, antioxidant, anti-inflammatory or antitumoral). To broaden the scope of their possible application, this study focused on testing Monascus pigment extracts as potential photosensitizing agents efficient in antimicrobial photodynamic therapy (aPDT) against bacteria. For this purpose, eight different extracts of secondary metabolites from the liquid- and solid-state fermentation of Monascus purpureus DBM 4360 and Monascus sp. DBM 4361 were tested against Gram-positive and Gram-negative model bacteria, Bacillus subtilis and Escherichia coli and further screened for ESKAPE pathogens, Staphylococcus aureus and Pseudomonas aeruginosa. To the bacterial culture, increasing concentration of extracts was added and it was found that all extracts showed varying antimicrobial activity against Gram-positive bacteria in dark, which was further increased after irradiation. Gram-negative bacteria were tolerant to the extracts' exposure in the dark but sensitivity to almost all extracts that occurred after irradiation. The Monascus sp. DBM 4361 extracts seemed to be the best potential candidate for aPDT against Gram-positive bacteria, being efficient at low doses, i.e. the lowest total concentration of Monascus pigments exhibiting aPDT effect was 3.92 ± 1.36 mg/L for E. coli. Our results indicate that Monascus spp., forming monascuspiloin as the major yellow pigment and not-forming mycotoxin citrinin, is a promising source of antimicrobials and photoantimicrobials.


Asunto(s)
Antibacterianos , Pruebas de Sensibilidad Microbiana , Monascus , Micelio , Monascus/química , Monascus/metabolismo , Antibacterianos/farmacología , Antibacterianos/química , Micelio/química , Micelio/efectos de la radiación , Micelio/efectos de los fármacos , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/química , Productos Biológicos/farmacología , Productos Biológicos/química , Bacterias Grampositivas/efectos de los fármacos , Bacterias Grampositivas/efectos de la radiación , Mezclas Complejas/farmacología , Mezclas Complejas/química , Pigmentos Biológicos/farmacología , Fotoquimioterapia
19.
Anal Chim Acta ; 1311: 342734, 2024 Jul 04.
Artículo en Inglés | MEDLINE | ID: mdl-38816163

RESUMEN

Photodynamic therapy (PDT), characterized by high treatment efficiency, absence of drug resistance, minimal trauma, and few side effects, has gradually emerged as a novel and alternative clinical approach compared to traditional surgical resection, chemotherapy and radiation. Whereas, considering the limited diffusion distance and short lifespan of reactive oxygen species (ROS), as well as the hypoxic tumor microenvironment, it is crucial to design photosensitizers (PSs) with suborganelle specific targeting ability and low-oxygen dependence for accurate and highly efficient photodynamic therapy. In this study, we have meticulously designed three PSs, namely CIH, CIBr, and CIPh, based on molecular engineering. Theoretical calculation demonstrate that the three compounds possess good molecular planarity with calculated S1-T1 energy gaps (ΔES1-T1) of 1.04 eV for CIH, 0.92 eV for CIBr, and 0.84 eV for CIPh respectively. Notably, CIPh showcases remarkable dual subcellular targeting capability towards lipid droplets (LDs) and mitochondria owing to the synergistic effect of lipophilicity derived from coumarin's inherent properties combined with electropositivity conferred by indole salt cations. Furthermore, CIPh demonstrates exclusive release of singlet oxygen (1O2)and highly efficient superoxide anion free radicals(O2⦁-) upon light irradiation supported by its smallest S1-T1 energy gap (ΔES1-T1 = 0.84 eV). This leads to compromised integrity of LDs along with mitochondrial membrane potential, resulting in profound apoptosis induction in HepG2 cells. This successful example of molecular engineering guided by density functional theory (DFT) provides valuable experience for the development of more effective PSs with superior dual targeting specificity. It also provides a new idea for the development of advanced PSs with efficient and accurate ROS generation ability towards fluorescence imaging-guided hypoxic tumor therapy.


Asunto(s)
Gotas Lipídicas , Mitocondrias , Fármacos Fotosensibilizantes , Especies Reactivas de Oxígeno , Humanos , Especies Reactivas de Oxígeno/metabolismo , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Gotas Lipídicas/química , Gotas Lipídicas/metabolismo , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/farmacología , Fotoquimioterapia , Supervivencia Celular/efectos de los fármacos
20.
Int J Nanomedicine ; 19: 4701-4717, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38808148

RESUMEN

Purpose: Numerous failures in melanoma treatment as a highly aggressive form of skin cancer with an unfavorable prognosis and excessive resistance to conventional therapies are prompting an urgent search for more effective therapeutic tools. Consequently, to increase the treatment efficiency and to reduce the side effects of traditional administration ways, herein, it has become crucial to combine photodynamic therapy as a promising therapeutic approach with the selectivity and biocompatibility of a novel colloidal transdermal nanoplatform for effective delivery of hybrid cargo with synergistic effects on melanoma cells. Methods: The self-assembled bilosomes, co-stabilized with L-α-phosphatidylcholine, sodium cholate, Pluronic® P123, and cholesterol, were designated, and the stability of colloidal vesicles was studied using dynamic and electrophoretic light scattering, also provided in cell culture medium (Dulbecco's Modified Eagle's Medium). The hybrid compounds - a classical photosensitizer (Methylene Blue) along with a complementary natural polyphenolic agent (curcumin), were successfully co-loaded, as confirmed by UV-Vis, ATR-FTIR, and fluorescent spectroscopies. The biocompatibility and usefulness of the polymer functionalized bilosome with loaded double cargo were demonstrated in vitro cyto- and phototoxicity experiments using normal keratinocytes and melanoma cancer cells. Results: The in vitro bioimaging and immunofluorescence study upon human skin epithelial (A375) and malignant (Me45) melanoma cell lines established the protective effect of the PEGylated bilosome surface. This effect was confirmed in cytotoxicity experiments, also determined on human cutaneous (HaCaT) keratinocytes. The flow cytometry experiments indicated the enhanced uptake of the encapsulated hybrid cargo compared to the non-loaded MB and CUR molecules, as well as a selectivity of the obtained nanocarriers upon tumor cell lines. The phyto-photodynamic action provided 24h-post irradiation revealed a more significant influence of the nanoplatform on Me45 cells in contrast to the A375 cell line, causing the cell viability rate below 20% of the control. Conclusion: As a result, we established an innovative and effective strategy for potential metastatic melanoma treatment through the synergism of phyto-photodynamic therapy and novel bilosomal-origin nanophotosensitizers.


Asunto(s)
Curcumina , Melanoma , Nanomedicina , Fotoquimioterapia , Fármacos Fotosensibilizantes , Neoplasias Cutáneas , Humanos , Neoplasias Cutáneas/tratamiento farmacológico , Melanoma/tratamiento farmacológico , Fotoquimioterapia/métodos , Línea Celular Tumoral , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/administración & dosificación , Curcumina/química , Curcumina/farmacología , Supervivencia Celular/efectos de los fármacos , Liposomas/química , Liposomas/farmacología , Colesterol/química , Fosfatidilcolinas/química , Fosfatidilcolinas/farmacología , Colato de Sodio/química , Sistemas de Liberación de Medicamentos/métodos , Poloxaleno/química , Poloxaleno/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA